Page last updated: 2024-08-18

pyrroles and Metabolic Syndrome

pyrroles has been researched along with Metabolic Syndrome in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	52 (57.78)	29.6817
2010's	37 (41.11)	24.3611
2020's	1 (1.11)	2.80

Authors

Authors	Studies
Abate, N; Chandalia, M; Jialal, I; Sallam, HS; Tuvdendorj, DR	1
Bousquet, P; Gomes, F; Gonçalves-de-Albuquerque, C; Machado, MV; Nascimento, AR; Tibiriçá, E	1
Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM	1
Bousquet, P; Chetrite, G; Fellmann, L; Fève, B; Gasparik, V; Gigou, L; Greney, H; Julien, C; Lacolley, P; Max, JP; Muscat, A; Niederhoffer, N; Oréa, V; Pizard, A; Regnault, V	1
Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP	1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A	1
Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H	1
Bao, W; Betteridge, DJ; Buchan, AP; Colhoun, H; DeMicco, DA; Durrington, PN; Fuller, JH; Hawa, MI; Hitman, GA; Leslie, RD; Neil, HA; Ola, T; Wun, CC	1
Bianchi, C; Chu, LM; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW	1
Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV	2
Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW	1
Alpini, G; Kumar, N; Meng, F; Mishra, J; Verma, RK	1
Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ	1
Antunes, B; Bousquet, P; Coelho, L; Daliry, A; Estato, V; Garzoni, L; Gomes, F; Nascimento, A; Rangel, R; Tibiriçá, E	1
Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Watts, GF	1
Deedwania, P; Singh, V	1
Devaraj, S; Jialal, I; Siegel, D; Singh, U	1
Ginsberg, HN; Ramakrishnan, R	1
Kékes, E	1
de Teresa, E; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martineau, P	1
Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C	1
Hsia, J; Otvos, JD; Rosenson, RS	1
Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE	1
Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF	1
Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K	1
Kirilmaz, A; Uzun, M; Yiğiner, O	1
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA	1
Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM	1
Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK	1
Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS	1
Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM	1
Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW	1
Hoenig, MR; Sellke, FW	1
Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B	1
Lakhin, DI; Vasil'eva, LV	1
Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS	1
Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Kakafika, A; Karagiannis, A; Kolovou, GD; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Petridis, D; Tziomalos, K	1
Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA	1
Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K	1
Elisaf, M; Katsiki, N	1
Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R	1
Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K	1
Saito, Y	1
Adamczak, M; Chudek, J; Czerwienska, B; Szotowska, M; Wiecek, A	1
Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF	1
Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M	1
Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW	1
Fujii, K; Masuyama, T	1
Loughrey, BV; McCance, DR; McGinty, A; Powell, LA; Young, IS	1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J	1
Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF	1
Barrett, PH; Chan, DC; O'Neill, FH; Thompson, GR; Watts, GF	1
Ballantyne, CM; Gumbiner, B; Hunninghake, DB; Maccubbin, DL; Mitchel, YB; Shah, AK	1
Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV	1
Benz, R; Suter, PM	1
Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH	1
Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C	1
Moreno Sánchez, D	1
Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M	2
Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Elisaf, MS; Milionis, HJ	1
Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K	1
Ballantyne, CM; Murin, J; Rose, H; Sarti, C; Stalenhoef, AF; Tonstad, S; Wilpshaar, W	1
Field, KM	1
Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M	1
Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K	1
Geiss, HC; Huptas, S; Otto, C; Parhofer, KG	1
Knopp, RH; Paramsothy, P	1
Scheen, AJ	1
Barter, P; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, SM; Haffner, S; Kastelein, JJ; LaRosa, JC; Schachner, H; Shepherd, J; Waters, DD	1
Athyros, VG; Elisaf, M; Ganotakis, ES; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Papageorgiou, AA; Tziomalos, K	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Hérnandez, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P	1
Buĭdina, TA; Khokhlov, AL; Zhilina, AN	1
Goldstein, MR	1
Mascitelli, L; Pezzetta, F	1
Bernardi, M; Caputo, F	1
Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Violi, F	1
Gorbas', IM; Iakimishina, LI; Kaĭdashev, IP; Petrushov, AV; Rasin, AM; Rasin, MS; Smirnova, IP; Vasil'ev, VN	1
Kaplan, SA	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P	1
Cizek, L; Horakova, D; Janout, V; Janoutova, G; Karpisek, M; Kollar, P; Kotolova, H; Lichnovska, R; Ochmanova, R; Stejskal, D; Yahia, RB	1
Das, S; Gidding, SS; Mitchell, D; Zhang, S	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Pirpasopoulou, A; Skaperdas, A; Tziomalos, K	1
Arca, M	1
Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ	1
Jukema, JW; Liem, AH; van de Woestijne, AP; Visseren, FL; Zwinderman, AH	1
Erkelens, DW	1

Reviews

9 review(s) available for pyrroles and Metabolic Syndrome

Article	Year
Do statins play a role in renoprotection? Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic	2014
Expanding roles for atorvastatin. Drugs of today (Barcelona, Spain : 1998), 2008, Volume: 44, Issue:6 Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke	2008
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
Pitavastatin: an overview. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL	2011
[Low HDL-cholesterol, high triglycerides--well known but often ignored]. Praxis, 2004, Nov-10, Volume: 93, Issue:46 Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization	2004
[Medical management of primary nonalcoholic fatty liver disease]. Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy, 2005, Volume: 25, Issue:10 Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2005
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke	2007
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia. Current diabetes reviews, 2005, Volume: 1, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States	2005

Trials

42 trial(s) available for pyrroles and Metabolic Syndrome

Article	Year
Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin. Journal of diabetes and its complications, 2020, Volume: 34, Issue:3 Topics: Adult; Aged; Amlodipine; Atorvastatin; Behavior Therapy; Biomarkers; Blood Pressure; Cardiometabolic Risk Factors; Combined Modality Therapy; Drug Combinations; Female; Heptanoic Acids; Humans; Life Style; Lipids; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Placebos; Pyrroles; Risk Reduction Behavior	2020
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes care, 2014, Volume: 37, Issue:6 Topics: Adult; Age of Onset; Aged; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucose Intolerance; Glutamate Decarboxylase; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Phenotype; Prevalence; Prospective Studies; Pyrroles; Risk Factors	2014
[Pleiotropic effects of atorvastatin and dynamics of quality of life characteristics in patients with hypertensive disease and metabolic syndrome]. Klinicheskaia meditsina, 2013, Volume: 91, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypertension; Metabolic Syndrome; Middle Aged; Pyrroles; Quality of Life; Treatment Outcome	2013
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:10 Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross-Over Studies; Double-Blind Method; Down-Regulation; Dyslipidemias; Fenofibrate; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Models, Biological; Pyrroles; Treatment Outcome; Triglycerides	2008
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. The American journal of cardiology, 2008, Aug-01, Volume: 102, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Metabolic Syndrome; Middle Aged; Monocytes; NF-kappa B; Oxidative Stress; Polyethylene; Pyrroles; Superoxides; Tyrosine	2008
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. The Journal of family practice, 2008, Volume: 57, Issue:10 Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome	2008
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. International journal of cardiology, 2010, Jul-23, Volume: 142, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors	2010
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes care, 2009, Volume: 32, Issue:6 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People	2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12 Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult	2009
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes care, 2009, Volume: 32, Issue:11 Topics: Atorvastatin; Cross-Over Studies; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoprotein(a); Lipoproteins, HDL; Male; Metabolic Syndrome; Nephelometry and Turbidimetry; Placebos; Pyrroles	2009
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk Metabolic syndrome and related disorders, 2009, Volume: 7, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). The American journal of cardiology, 2010, Feb-01, Volume: 105, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome	2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes care, 2010, Volume: 33, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin	2010
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult	2010
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. The Korean journal of internal medicine, 2010, Volume: 25, Issue:1 Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes care, 2010, Volume: 33, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Metabolic Syndrome; Plasminogen Activator Inhibitor 1; Prediabetic State; Pyrroles	2010
[Effect of atorvastatin (liptonorm) on indicators of the lipid spectrum of blood in patients with the metabolic syndrome]. Advances in gerontology = Uspekhi gerontologii, 2010, Volume: 23, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2010
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Current vascular pharmacology, 2011, Volume: 9, Issue:6 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors	2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of neurology, 2011, Volume: 68, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult	2011
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Current medical research and opinion, 2011, Volume: 27, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Uric Acid	2011
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology, 2012, Volume: 63, Issue:5 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Time Factors; Treatment Outcome	2012
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Adult; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Pyrroles	2012
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:12 Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional	2012
Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial. Clinical endocrinology, 2013, Volume: 79, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL11; Chemokine CCL2; Chemokine CCL4; Chemokines, CC; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; Monocytes; Pyrroles; Receptors, CCR5; RNA, Messenger	2013
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes, 2003, Volume: 52, Issue:3 Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides	2003
Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, Volume: 27, Issue:7 Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, VLDL; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Pyrroles	2003
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical therapeutics, 2003, Volume: 25, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Time Factors; Triglycerides	2003
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American journal of cardiology, 2005, Feb-01, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis, 2005, Volume: 181, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation	2005
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior	2005
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. European heart journal, 2005, Volume: 26, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes care, 2005, Volume: 28, Issue:10 Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome	2005
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss	2006
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. The American journal of cardiology, 2006, Jul-01, Volume: 98, Issue:1 Topics: Adult; Atorvastatin; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Pyrroles; Treatment Outcome	2006
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare? Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:3 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors	2006
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors	2007
[Atorvastatin in correction of metabolic syndrome: clinico-economical assessment of efficacy]. Kardiologiia, 2006, Volume: 46, Issue:11 Topics: Atorvastatin; Costs and Cost Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome	2006
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American heart journal, 2007, Volume: 153, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2007

Other Studies

40 other study(ies) available for pyrroles and Metabolic Syndrome

Article	Year
I Autonomic neuroscience : basic & clinical, 2019, Volume: 217 Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diet, High-Fat; Disease Models, Animal; Heart Rate; Imidazoline Receptors; Lipids; Male; Metabolic Syndrome; Microcirculation; Pyrroles; Rats; Rats, Wistar; Sympathetic Nervous System	2019
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. Journal of hepatology, 2013, Volume: 59, Issue:1 Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles	2013
A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 346, Issue:3 Topics: 3T3-L1 Cells; Adiponectin; Aniline Compounds; Animals; Blood Pressure; Body Weight; Glucose Intolerance; Glucose Tolerance Test; Imidazoline Receptors; Insulin Resistance; Kidney; Lipids; Male; Metabolic Syndrome; Mice; Pyrroles; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Surface Plasmon Resonance; Sympathetic Nervous System	2013
Are statins 'IDEAL' for non-alcoholic fatty liver disease? Current medical research and opinion, 2014, Volume: 30, Issue:2 Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides	2014
APOE3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6* Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones	2014
Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome. The Journal of thoracic and cardiovascular surgery, 2014, Volume: 148, Issue:6 Topics: Animals; Atorvastatin; Autophagy; Biomarkers; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Pyrroles; Signal Transduction; Swine	2014
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome]. Kardiologiia, 2014, Volume: 54, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome	2014
Atorvastatin regulates apoptosis in chronically ischemic myocardium. Journal of cardiac surgery, 2015, Volume: 30, Issue:2 Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature	2015
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome. The Journal of biological chemistry, 2015, Dec-04, Volume: 290, Issue:49 Topics: Animals; Body Weight; Caco-2 Cells; Cytokines; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; Glucose Tolerance Test; Humans; Immunity, Innate; Inflammation; Insulin; Janus Kinase 3; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Obesity; Organ Size; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Signal Transduction; Toll-Like Receptors	2015
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, Volume: 75, Issue:5 Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides	2016
Cerebral Microvascular Dysfunction and Inflammation Are Improved by Centrally Acting Antihypertensive Drugs in Metabolic Syndrome. Metabolic syndrome and related disorders, 2017, Volume: 15, Issue:1 Topics: Aniline Compounds; Animals; Antihypertensive Agents; Brain; Cerebrovascular Circulation; Clonidine; Diet, High-Fat; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Microcirculation; NADPH Oxidases; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Inbred WKY; Sympatholytics; Vascular Cell Adhesion Molecule-1	2017
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:10 Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Down-Regulation; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Pyrroles; Research Design; Treatment Outcome; Triglycerides	2008
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:10 Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome	2009
The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:5 Topics: Adult; Alanine Transaminase; Atorvastatin; Contraindications; Coronary Artery Disease; Fatty Liver; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pyrroles	2009
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Microcirculation (New York, N.Y. : 1994), 2009, Volume: 16, Issue:8 Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors	2009
Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis, 2010, Volume: 211, Issue:1 Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles	2010
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology, 2011, Volume: 62, Issue:2 Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles	2011
Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. Current medical research and opinion, 2011, Volume: 27, Issue:8 Topics: Atorvastatin; Cholesterol, LDL; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Pyrroles; Uric Acid	2011
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome. PloS one, 2011, Volume: 6, Issue:9 Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones	2011
Effect of low-dose atorvastatin on plasma concentrations of adipokines in patients with metabolic syndrome. Kidney & blood pressure research, 2012, Volume: 35, Issue:4 Topics: Adipokines; Adult; Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome	2012
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. The Journal of thoracic and cardiovascular surgery, 2012, Volume: 144, Issue:6 Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Biomarkers; Collateral Circulation; Coronary Circulation; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Metabolic Syndrome; Microvessels; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Neovascularization, Physiologic; Oxidative Stress; Pyrroles; Signal Transduction; Swine; Swine, Miniature; Vasodilation; Vasodilator Agents	2012
Who benefits from statins? Patient or focal plaque? Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:12 Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines	2012
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome]. Kardiologiia, 2003, Volume: 43, Issue:3 Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome	2003
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Aged; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation	2005
Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.). American heart journal, 2005, Volume: 150, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Pyrroles; Simvastatin	2005
Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens. Cardiology, 2005, Volume: 104, Issue:4 Topics: Acetylcholine; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation	2005
Does the metabolic syndrome help to select patients requiring high statin dose? Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Incidence; Metabolic Syndrome; Patient Selection; Pyrroles; Risk Assessment; Risk Factors	2006
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluati Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:1 Topics: Aged; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Creatinine; Female; Glomerular Filtration Rate; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Uric Acid	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Randomized Controlled Trials as Topic	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Aged; Atorvastatin; Coronary Disease; Diet, Mediterranean; Female; Heptanoic Acids; Humans; Life Style; Metabolic Syndrome; Pyrroles	2007
Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Ethanol; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles	2007
Statins enhance circulating vitamin E. International journal of cardiology, 2008, Jan-11, Volume: 123, Issue:2 Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Pyrroles; Retrospective Studies; Simvastatin; Vitamin E	2008
[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine]. Likars'ka sprava, 2006, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Body Weight; Cardiovascular Diseases; Heptanoic Acids; Humans; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Rural Health; Rural Population; Ukraine	2006
Metabolic dysfunction and male pelvic health. European urology, 2007, Volume: 52, Issue:2 Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Prostatic Hyperplasia; Pyrroles; Urination Disorders	2007
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. European journal of clinical investigation, 2007, Volume: 37, Issue:8 Topics: Adipocytes; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Fatty Acid-Binding Proteins; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles	2007
Metabolic syndrome with early aortic atherosclerosis in a child. Journal of the cardiometabolic syndrome, 2006,Summer, Volume: 1, Issue:4 Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides	2006
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids, 2007, Volume: 42, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regression Analysis; Risk Factors; Triglycerides	2007
Determinants of CRP level in statin-treated patients. Current medical research and opinion, 2008, Volume: 24, Issue:4 Topics: Atorvastatin; Blood Pressure; C-Reactive Protein; Enzyme Inhibitors; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides	2008
Insulin resistance syndrome and type 2 diabetes mellitus. The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate	2001